stress test model
stress test model compani announc receiv
complet respons letter fda applic gener advair
setback come heel myl approv first-to-market biosimilar
amgn neulasta pegfilgrastim compani expect launch immin
still good chanc win approv gener advair year-end
sinc defici applic minor financi contribut like
rel modest mani investor took comfort repres best
worst-cas scenario sinc approv seem inevit immin share
pressur concern regard number
still see path mgmt rang note mgmt incent reach
seem depend opportun like restasi suboxon
materi lower ep estim mark growth though
remain larg unchang sinc see momentum build good
visibl neulasta approv progress advair
delay gener advair setback better posit mitig
impact last year price competit environ gener
improv price deflat moder mid-teen mid-singl digit
level addit analysi show myl gener portfolio less top heavi
top product go sale make less vulner
price competit headwind also last year saw worse-than-expect eros
myl epipen franchis brand author gener saw share loss
recov share late competitor face suppli
limit launch gener copaxon slower expect sandoz
approv slow myl progress market share nrx reach
despit fx headwind european busi strong contributor
esp brand ad meda epd model gener restasi suboxon
product could launch offer upsid
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
overweight built pipelin new
product opportun continu believ
appreci investor believ
valuat reflect compani abil
navig near-term headwind gener
diversif buffer challeng
execut key pipelin opportun
gener version estrac restasi advair
biosimilar neulasta would result posit
earn revis also success would
increas confid grow
continu price eros gener market
addit inabl execut key gener
growth believ would result multipl
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
myl announc fda inform compani go receiv
complet respons letter anda gener advair brought flash back
compani receiv complet respons letter first cycl review howev
unlik last year myl better posit deliv strong financi perform despit
setback perhap importantli competit dynam gener industri
much stronger price eros improv show stabil addit
setback advair come heel myl approv first-to-market biosimilar
amgn neulasta pegfilgrastim compani expect launch immin
still good chanc win approv year-end defici
minor financi contribut like rel modest
still see path mgmt rang note manag incent
reach order achiev long-term compens seem
depend opportun like restasi suboxon materi lower
estim mark growth though remain larg unchang
sinc see momentum build good visibl neulasta approv
progress advair share trade new estim
estim see littl downsid current level signific upsid multipl
expans investor becom comfort myl earn power
unlik seen market biosimilar adopt acut set gcsf
strong includ teva granix non-brand gcsf gain market
share zarxio gain share within month even granix alreadi
market share see better proxi adopt biosimilar neulasta next
year herceptin addit note hospit incentiv use
biosimilar repres roughli neulasta volum albeit discount level
total gcsf sale market share non-brand gcsf zarxio
wac price comparison granix zarxio
epipen stabl even regain share
one headwind myl busi declin epipen relat
compani launch author gener well share loss
dont view epipen franchis long-term growth driver
compani stand benefit year suppli shortag experienc
led recoveri market share expect recov suppli
import back-to-school season time stand benefit
epipen recov market share follow shortag
last year unabl win approv gener advair first cycl
review compani expos without key product launch period
signific disloc gener market year later situat differ
 gener show much improv price dynam sinc begin
year may data continu trend show stabil price reinforc
view base busi gener manufactur found bottom data
analysi continu show histor norm mid single-digit price deflat seem
return even better price new product launch remain lifeblood
industri see well best posit capit stabil
base drive meaning growth respect pipelin
look y/i price chang drug product group show us price stabil
difficult base given larg overal price decreas seen like
well continu see moder y/i price declin seen thu far
rel easi comparison
line graph distribut price chang ndc
incorpor analysi note chart vast major ndc
experienc price deflat product price increas number
continu trend well manufactur last three month
signific increas averag seen
distribut y/i price chang may may
also examin number m/m price increas saw similar trend toward lack
volatil may ndc analyz price movement
versu april march attribut lack
volatil multipl factor includ disciplin price launch strategi
manufactur commentari manag includ teva
confirm approach custom renegoti rate focus
profit versu volum
distribut m/m price chang april march februari
though myl us gener portfolio rel diversifi still compos nearli
immedi releas oral solid dosag given diversif portfolio gener
price data provid good pictur experienc us market
importantli myl key us gener product also shown rel lack volatil
provid stabl revenu stream particular product gener
epipen levothyroxin product physician patient hesit
switch manufactur thu give addit assur revenu
myl portfolio becom much less concentr sinc number product
quarterli revenu declin period
myl transit product grown though revenu top
product declin base busi stay
rel constant revenu transit
product grown
face difficult price environ myl base busi shown much
durabl us base busi grown revenu
number product base busi increas time
myl base busi portfolio expand averag revenu per product declin
y/i
myl abil maintain share product high revenu produc
shown transit product product quarterli
revenu myl transit product averag per quarter sinc show
abl avoid complet eros top product maintain share
competitor enter market like gener manufactur immun
rapid eros key asset spike top product larg due
benicar gener declin sharpli competitor enter market
us split top transit base product data label indic product within categori
clearli ideal lose much share top product seem
make best bad situat maintain share revenu
product given stabil base transit see opportun
leverag deep pipelin impend launch support growth
much myl row busi depend antiretrovir portfolio
want focu eu segment midpoint manag guidanc
guid high singl digit revenu growth sinc complet
meda acquisit august abbott establish product busi
built much larger diversifi eu busi prior busi
larg focus solid-or dose gener roughli half busi
concentr franc
current portfolio brand gener over-the-counter product europ
product greater eu net sale analysi segment show
larg abl weather eu price headwind abl take
maintain signific share key geographi franc germani itali
conjunct abl maintain volum larg across europ well
signific price pressur european gener market wake
financi crisi govern mandat price cut competit tender
market becam aggress recent year region proven much stabl
analyz list price myl product across eu found myl averag gener
price per unit steadili climb key countri sinc except
spain latter half believ iqvia methodolog measur unit
price inflat price level though corrobor commentari manufactur
said price stable/down modestli price gener similar brand start
lower level europ eros didnt mirror seen market
franc outlier term price number gener manufactur term
volum market valu prescript volum prescript valu countri
approxim revenu franc come gener product balanc
come over-the-counter brand product contrast product mix itali
germani uk reli much heavili brand prescript product
averag gener price per unit time eu
analyz gener volum data found sinc maintain
volum across eu spain declin germani declin
except drop germani driven decreas volum
commodit gener product citalopram pantoprazol simvastatin
chang gener product volum sinc
brand side key brand eu note influvac becom
signific contributor sale flu season sale approach
even volatil product myl eu segment proven
steadi sale segment sale
includ estim declin influvac q/q creon repres anoth
stabl brand much like levothyroxin us patient gener sticki
product creon use replac pancreat enzym cystic fibrosi patient
pancreat insuffici capsul must taken everi meal
dose depend size meal exampl patient may take unit
capsul small snack two unit capsul larg meal like dinner
multipl pancreat enzym replac product market given
complex dose regimen patient tend stay start final dymista
intranas product season allergi also show signific growth sale
grew accord iqvia sale track significantli
higher sale april alon
iqvia quarterli eu revenu brand asset
franc germani myl import eu countri term sale current
market leader franc sale forc cover hospit
pharmaci within countri sale grew y/i product
gener zosyn ceftriaxon catalyz growth germani show larg spike
due influvac accord iqvia sale quarter itali spain
uk repres area possibl growth over-the-counter busi countri
minim manag state prioriti move forward increas over-the-counter
row segment japan australia import countri
presenc note non-rx sale japan growth japan
australia grew modest
franc iqvia gener revenu broken categori
germani iqvia gener revenu broken
itali iqvia gener revenu broken categori
uk iqvia gener revenu broken categori
spain iqvia gener revenu broken categori
japan iqvia gener revenu broken categori
dougla tsao herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
